Results 21 to 30 of about 61,821 (357)
Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV
Antibodies, 2019 In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct.
Lili Wang +10 more
doaj +1 more source
Cancer immunomodulation using bispecific aptamers
Molecular Therapy: Nucleic Acids, 2022 Evasion of immune destruction is a major hallmark of cancer. Recent US Food and Drug Administration (FDA) approvals of various immunomodulating therapies underline the important role that reprogramming the immune system can play in combating this disease.
Brian J. Thomas +2 more
doaj +1 more source
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]
, 2018 Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B. +5 more
core +2 more sources
THE ALBUMIN-BINDING DOMAIN AS A SCAFFOLD FOR PROTEIN ENGINEERING
Computational and Structural Biotechnology Journal, 2013 The albumin-binding domain is a small, three-helical protein domain found in various surface proteins expressed by gram-positive bacteria. Albumin binding is important in bacterial pathogenesis and several homologous domains have been identified.
Johan Nilvebrant, Sophia Hober
doaj +1 more source
Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. [PDF]
, 2014 Trop2 is a transmembrane glycoprotein encoded by the Tacstd2 gene. It is an intracellular calcium signal transducer that is differentially expressed in many cancers. It signals cells for self-renewal, proliferation, invasion, and survival.
Bonavida, Benjamin, Shvartsur, Anna
core +2 more sources
Antibodies, 2013 The DOCK-AND-LOCKTM (DNLTM) method provides a modular approach to develop multivalent, multifunctional complexes of defined structures, of which bispecific hexavalent antibodies (bsHexAbs) are prominent examples with potential applications in targeted ...
Chien-Hsing Chang +4 more
doaj +1 more source
Frontiers in Immunology, 2022 Immunotherapy with T cells genetically modified with chimeric antigen receptors (CARs) has shown significant clinical efficacy in patients with relapsed/refractory B-cell lymphoma.
Ana Carolina Caballero +13 more
doaj +1 more source
Single-domain antibodies and their formatting to combat viral infections [PDF]
, 2018 Since their discovery in the 1990s, single-domain antibodies (VHHs), also known as NanobodiesA (R), have changed the landscape of affinity reagents. The outstanding solubility, stability, and specificity of VHHs, as well as their small size, ease of ...
Ballegeer, Marlies +4 more
core +2 more sources
Frontiers in Immunology, 2023 T cell engagers, a category of T cell-retargeting immunotherapy, are rapidly transforming clinical cancer care. However, the lack of tumor-specific targets poses a significant roadblock for broad adaptation of this therapeutic modality in many ...
Even Walseng +7 more
doaj +1 more source
Cell-type specific potent Wnt signaling blockade by bispecific antibody. [PDF]
, 2018 Cell signaling pathways are often shared between normal and diseased cells. How to achieve cell type-specific, potent inhibition of signaling pathways is a major challenge with implications for therapeutic development.
Bidlingmaier, Scott +6 more
core +2 more sources